The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).
 
Hazel Lote
No Relationships to Disclose
 
Florentia Mousoullou
No Relationships to Disclose
 
George Vlachogiannis
No Relationships to Disclose
 
Caroline Fong
Honoraria - Bristol-Myers Squibb
 
Laura Satchwell
No Relationships to Disclose
 
Clare Peckitt
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Shannon Kidd
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Lilly (Inst)
 
Susan Cromarty
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Lilly (Inst)
 
Anderley Gordon
No Relationships to Disclose
 
Charlotte Victoria Fribbens
No Relationships to Disclose
 
David J. Watkins
No Relationships to Disclose
 
Sheela Rao
Consulting or Advisory Role - Bayer; Roche
Travel, Accommodations, Expenses - Bayer; Incyte; Servier
 
Ian Chau
Honoraria - Eisai; Lilly; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - Guardant Health; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Nicola Valeri
No Relationships to Disclose